» Articles » PMID: 20479941

Modulation of IL-17 and Foxp3 Expression in the Prevention of Autoimmune Arthritis in Mice

Overview
Journal PLoS One
Date 2010 May 19
PMID 20479941
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Rheumatoid Arthritis (RA) is a chronic immune mediated disease associated with deregulation of many cell types. It has been reported that different T cell subsets have opposite effects in disease pathogenesis, in particular Th17 and Treg cells.

Methodology And Findings: We investigated whether non-depleting anti-CD4 monoclonal antibodies, which have been reported as pro-tolerogenic, can lead to protection from chronic autoimmune arthritis in SKG mice--a recently described animal model of RA--by influencing the Th17/Treg balance. We found that non-depleting anti-CD4 prevented the onset of chronic autoimmune arthritis in SKG mice. Moreover, treated mice were protected from the induction of arthritis up to 60 days following anti-CD4 treatment, while remaining able to mount CD4-dependent immune responses to unrelated antigens. The antibody treatment also prevented disease progression in arthritic mice, although without leading to remission. Protection from arthritis was associated with an increased ratio of Foxp3, and decreased IL-17 producing T cells in the synovia. In vitro assays under Th17-polarizing conditions showed CD4-blockade prevents Th17 polarization, while favoring Foxp3 induction.

Conclusions: Non-depleting anti-CD4 can therefore induce long-term protection from chronic autoimmune arthritis in SKG mice through reciprocal changes in the frequency of Treg and Th17 cells in peripheral tissues, thus shifting the balance towards immune tolerance.

Citing Articles

Mechanism underlying the action of Duanteng-Yimu Tang in regulating Treg/Th17 imbalance and anti-rheumatoid arthritis.

Feng W, Wan X, Fan S, Liu C, Zheng X, Liu Q Heliyon. 2023; 9(5):e15867.

PMID: 37206012 PMC: 10189174. DOI: 10.1016/j.heliyon.2023.e15867.


Oral dextran sulfate sodium administration induces peripheral spondyloarthritis features in SKG mice accompanied by intestinal bacterial translocation and systemic Th1 and Th17 cell activation.

Tabuchi Y, Katsushima M, Nishida Y, Shirakashi M, Tsuji H, Onizawa H Arthritis Res Ther. 2022; 24(1):176.

PMID: 35879738 PMC: 9310491. DOI: 10.1186/s13075-022-02844-4.


Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective.

Zwicky P, Unger S, Becher B J Exp Med. 2019; 217(1).

PMID: 31727781 PMC: 7037236. DOI: 10.1084/jem.20191123.


Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I.

Ghosh A, Liao A, OLeary C, Mercer J, Tylee K, Goenka A Mol Ther Methods Clin Dev. 2019; 13:321-333.

PMID: 30976609 PMC: 6441787. DOI: 10.1016/j.omtm.2019.02.007.


Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis.

Takahashi S, Saegusa J, Sendo S, Okano T, Akashi K, Irino Y Arthritis Res Ther. 2017; 19(1):76.

PMID: 28399896 PMC: 5387190. DOI: 10.1186/s13075-017-1283-3.


References
1.
Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

2.
Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H . High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol. 2000; 164(5):2832-8. DOI: 10.4049/jimmunol.164.5.2832. View

3.
Choy E, Connolly D, Rapson N, Jeal S, Brown J, Kingsley G . Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford). 2000; 39(10):1139-46. DOI: 10.1093/rheumatology/39.10.1139. View

4.
Jacobs J, Wu H, Benoist C, Mathis D . IL-17-producing T cells can augment autoantibody-induced arthritis. Proc Natl Acad Sci U S A. 2009; 106(51):21789-94. PMC: 2799826. DOI: 10.1073/pnas.0912152106. View

5.
Ranges G, Sriram S, Cooper S . Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med. 1985; 162(3):1105-10. PMC: 2187818. DOI: 10.1084/jem.162.3.1105. View